Clinical Trials Sponsored by Celéri Health, Inc.

Total 3250 results

Bausch Health Americas, Inc.

Withdrawn

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Pancreatic Cancer
Intermountain Health Care, Inc.

Terminated

PLUG Dementia Trial and MRI PLUG Dementia Sub-Study

Atrial Fibrillation | Dementia | Cognitive Decline

United States
Bausch Health Americas, Inc.

Completed

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

Acne Vulgaris

United States, Canada
Genomic Health®, Inc.

Terminated

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

United States, Spain, Chile, France, Ireland, Japan, United Kingdom
United Health Products, Inc.

Completed

Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting

Bleeding | Hemostasis

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Bausch Health Americas, Inc.

Completed

Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea

HIV Enteropathy | Diarrhea With HIV

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

Psoriasis

United States
EicOsis Human Health Inc.

Unknown

Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)

COVID-19

United States
Intermountain Health Care, Inc.

Completed

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction (WONDERFUL)

Intermittent Fasting

United States
Intermountain Health Care, Inc.

Completed

Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)

Sepsis | Septic Shock

United States
Intermountain Health Care, Inc.

Completed

CGM - Reimagine Primary Care

Diabetes Mellitus, Type 2

United States
LifeBridge Health
Orthosensor, Inc.

Withdrawn

To Determine the Gait and Functional Improvement in Total Knee Arthroplasty (Orthosensor)

Degenerative Arthritis

United States
Intermountain Health Care, Inc.

Completed

I USE LR in the ED

Kidney Injury

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis

Myopia

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Withdrawn

Study Evaluating MOA-728 Administered in Healthy Men

Healthy
Bausch Health Americas, Inc.

Withdrawn

Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy

Methadone-maintenance Subjects

United States
Bausch Health Americas, Inc.

Completed

Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization

Healthy Volunteers

United States
Bausch Health Americas, Inc.

Completed

Tolerance and Pharmacokinetics Study of MNTX Tablets

Normal Healthy Volunteers

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis

Tinea Corporis

Dominican Republic, Honduras
Bausch Health Americas, Inc.

Completed

Open-Label Treatment Extension of Protocol MNTX 302

Terminal Illness

United States
Bausch Health Americas, Inc.

Completed

Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Bausch Health Americas, Inc.

Completed

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

Bowel Dysfunction

United States
Bausch Health Americas, Inc.

Completed

Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects

Healthy

United States
Bausch Health Americas, Inc.

Completed

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Bausch Health Americas, Inc.

Completed

Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis

Ulcerative Colitis | Inflammatory Bowel Disease

United States
Bausch Health Americas, Inc.

Completed

Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone

Metahdone-maintenance Subjects

United States
Bausch Health Americas, Inc.

Completed

Bioequivalence Study in Healthy Volunteers

Healthy

United States
Bausch Health Americas, Inc.

Completed

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

Irritable Bowel Syndrome | Colonic Diseases | Diarrhea | Gastrointestinal Disease

United States
Bausch Health Americas, Inc.

Completed

Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects

Constipation

United States
Bausch Health Americas, Inc.

Terminated

Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

Psychosis | Velo-cardio-facial Syndrome

United States
Bausch Health Americas, Inc.

Completed

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

Irritable Bowel Syndrome With Diarrhea

United States
Bausch Health Americas, Inc.

Completed

Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring

Acne Vulgaris

Canada
Bausch Health Americas, Inc.

Completed

Canadian Aesthetic Experience With Sculptra Therapy

Skin Aging

Canada
Bausch Health Americas, Inc.

Completed

PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers

Healthy

United States
Bausch Health Americas, Inc.

Completed

Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel

Acne Vulgaris

United States
Bausch Health Americas, Inc.

Completed

A Study of a New Drug Treatment for Acne

Acne Vulgaris

United States
Bausch Health Americas, Inc.

Completed

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

Ulcerative Colitis | Inflammatory Bowel Disease

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Proctitis | Proctosigmoiditis

United States
Bausch Health Americas, Inc.

Terminated

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

Proctitis | Proctosigmoiditis

United States
Bausch Health Americas, Inc.

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Psoriasis
Intermountain Health Care, Inc.

Completed

Indoor Air Quality and Respiratory Symptoms in Former Smokers

Chronic Obstructive Pulmonary Disease

United States
Bausch Health Americas, Inc.

Completed

Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects

Exposure

United States
Rinovum Women's Health, Inc.

Completed

Disposable Stress Urinary Incontinence Pessary Device Study

Stress Urinary Incontinence

United States
Intermountain Health Care, Inc.

Completed

Response to Medication Registry

Adverse Drug Events

United States

3

Subscribe